Microbot Medical to Enhance Focus on its Core Business and Prioritize Preparations for Regulatory and First in Human Clinical Cases Company will enable focus on its LIBERTY technology through the introduction of the Core

Medical to Enhance Focus on its Core Business and Prioritize

Preparations for Regulatory and First in Human Clinical Cases

will enable focus on its LIBERTY technology through the introduction of the Core Business Focus Program coupled with cost restructuring

Mass., May 18, 2023 - Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY Robotic Surgical

System, the first single-use endovascular robotic system, today announced its Core Business Focus Program and cost restructuring plan

to continue enhancing the focus on its core technology while maximizing available resources to support it. This includes the focus on

completing the validation and verification process and completing the planned first- in- human (FIH) clinical cases

with its LIBERTY Robotic Surgical System, both expected during the second half of 2023.

part of the Core Business Focus Program, and to maximize available resources, the Company will eliminate non-core technology expenses

by terminating agreements relating to the TipCat, ViRob and CardioSert technologies. In addition, it executed several cost

reduction initiatives to reduce expenses that are not directly supporting the Company's core technology, including

reduction in positions not directly supporting the core LIBERTY technology and compensation reductions or restructurings for

its leadership team and certain advisors.

information about the Company's Core Business Focus Program and cost restructuring plan, as well as other information about the

Company's results of operations and financial condition, can be found in its Quarterly Report on Form 10-Q for the fiscal quarter

ended March 31, 2023, filed with the Securities and Exchange Commission on May 17, 2023.

Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,

with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within

LIBERTY Robotic System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the

need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The Company believes

the LIBERTY Robotic System's remote operation has the potential to be the first system to democratize endovascular interventional

information about Microbot Medical is available at http://www.microbotmedical.com.

to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities

for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or

prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform

Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that

contain words such as "will," "believes," "plans," "anticipates," "expects"

and "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and

uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of LIBERTY,

the outcome of its studies to evaluate LIBERTY, whether the Company's core business focus program and cost reduction plan are

sufficient to enable the Company to continue to focus on its LIBERTY technology while it seeks additional working capital, any failure

or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory studies which could adversely

affect or delay such studies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals,

uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property

rights. Additional information on risks facing Microbot Medical can be found under the heading "Risk Factors" in Microbot

Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web

site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required